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Dengue  virus  (DENV)  is  the  most  prevalent  arbovirus  in  the  world,  found  mainly  in  tropical  regions.  As
clinical  manifestations  present  frequently  as  nonspeciﬁc  febrile  illness,  laboratory  diagnosis  is  essential
to  conﬁrm  DENV  infections  and  for epidemiological  studies.  Recombinant  envelope  (E)  antigens  of  four
serotypes  of  DENV  were  used  to  develop  an  immunoglobulin  G  enzyme-linked  immunosorbent  assay
(IgG-ELISA).  To evaluate  the  IgG-ELISA,  a panel  of serum  samples  that  had  been  tested  previously  by
a  plaque  reduction  neutralization  test (PRNT)  was  investigated  for  the presence  of  anti-E  antibodies
against  the  four  DENV  serotypes.  IgG-ELISA  was  found  to  have  a sensitivity  (91%)  and  speciﬁcity  (98%)  atengue virus
erology
iagnosis
LISA
ecombinant envelope proteins
a  receiver-operating  characteristic  (ROC)  optimized  cutoff  and  demonstrated  high  performance  as  well
as  good  indexes.  A concordance  of  97%  was  achieved  between  both  assays,  and  only  21/704  (3%)  samples
were  not  concordant.  The  results  of  the  present  study  demonstrate  a moderate  correlation  between
neutralizing  antibody  titers  and  IgG-ELISA  values.  These  ﬁndings  indicate  that  the  recombinant  protein-
based  IgG-ELISA  is  a suitable  method  for  routine  serodiagnosis,  monitoring  and  seroepidemiological
studies  of DENV  infections.. Introduction
Dengue virus (DENV), a member of the family Flaviviridae, is the
ost prevalent mosquito-borne viral disease in tropical and sub-
ropical regions of the world. Nearly 2.5 billion people in more
han 100 countries live in dengue-endemic regions, which include
he Caribbean, South and Central America, Africa, and Southeast
sia (Gubler, 2002). Approximately 100 million cases of dengue
nfections, including an estimated 250,000–500,000 severe cases of
engue hemorrhagic fever or dengue shock syndrome and approx-
mately 25,000 deaths occur annually in the world (Halstead,
007). According to the Pan American Health Organization (PAHO),
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dengue killed 1167 individuals in Latin America in 2010, and 1.8
million cases were conﬁrmed.
There are four serotypes of Dengue virus: DENV-1, DENV-2,
DENV-3, and DENV-4. Infection with one DENV induces lifelong
protective immunity to the serotype of the virus that produced the
infection. To date, no effective commercial vaccine or treatment
exists for dengue infections, so early detection, epidemiological
studies, and the management of severe disease are essential to pre-
vent death (Deen et al., 2006). Therefore, health care resources, such
as clinical and laboratory diagnosis and hospital admissions, repre-
sent a ﬁnancial burden to many countries where dengue is endemic,
including Brazil.
The  detection of antibodies by serological methods is very use-
ful for dengue diagnosis. There are a variety of serological tests that
Open access under the Elsevier OA license.can measure anti-DENV antibodies including the hemagglutination
inhibition test, complement ﬁxation test, ﬂuorescent antibody test,
enzyme-linked immunosorbent assay (ELISA), and plaque reduc-
tion neutralization test (PRNT). However, only PRNT measures the
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iological parameter of in vitro virus neutralization, and for this rea-
on, it is the most virus speciﬁc serologic test among the ﬂaviviruses
WHO, 2007). PRNT is a serotype-speciﬁc test for DENV, correlating
ell with serum levels of protection from viral infection (Guzmán
nd Kourí, 2004). Indeed, PRNT is regarded as the “gold standard”
erological method for the diagnosis of DENV (Thomas et al., 2009).
uantitative PRNT values demonstrate a good correlation with the
atient’s immune state prior to DENV serotype infection and cross-
eaction to other serotypes (Morens et al., 1985). However, PRNT
as some practical disadvantages because it is technically demand-
ng, labor intensive and time consuming. In addition, as a variable
ioassay, the test is difﬁcult to standardize between different lab-
ratories. ELISA, however, is rapid, simple to perform, relatively
nexpensive, easier to standardize and, importantly, can be auto-
ated. However, there are a lack of data describing the sensitivity
nd speciﬁcity of IgG-ELISA compared to PRNT for dengue anti-
ody detection. To date, there are no published technical efﬁcacy
rials correlating the presence of neutralizing antibodies and IgG
etected by immunoenzymatic assays.
Although PRNT may  be the most useful serological method
or detecting serotype-speciﬁc antibodies, it employs a DENV-
nfected cell culture supernatant that increases the risk of potential
ealth hazards via exposure to infectious virus particles. For this
eason, the simpliﬁed production of recombinant proteins or syn-
hetic peptides in bacteria has been proposed as an antigen source
dos Santos et al., 2004), which is often the limiting reagent in
ENV diagnostic assays. Indeed, the use of recombinant proteins
s antigens avoids the problems associated with whole-virus DENV
ntigen preparations (Videa et al., 2005).
The serological method developed in this study utilizes recom-
inant E proteins of DENV as antigens. These proteins have already
een proven to elicit protective antibodies in mice and monkeys
Clements et al., 2010; Men  et al., 2000, 1991; Putnak et al., 2005;
utnak, 1994; Raviprakash et al., 2000) and have been used as an
ntigen in the rapid diagnosis of DENV infection (Makino et al.,
991). Most recombinant DNA-based strategies focus on the E pro-
ein because it is the major DENV structural protein that is known
o contain the principal neutralizing epitopes, and it is considered
o be the viral immunodominant protein (Lai et al., 2008; Lin et al.,
994).
The present work describes the development and evaluation
f an indirect ELISA based on DENV E recombinant proteins of
ll four serotypes as a tool for diagnosis and seroepidemiological
tudies.
. Materials and methods
.1. Serum samples
In this study, an IgG-ELISA was evaluated using 704 serum
pecimens obtained from the Secretaria Municipal de Saúde of
elo Horizonte. From June 2006 until March 2007, samples were
ollected randomly from healthy volunteers in Belo Horizonte
Minas Gerais State, Brazil), an endemic area for DENV 1–3.
he samples were stored at −20 ◦C for later use. All of the 704
amples were screened previously for neutralizing antibodies by
RNT in a blind panel, and a detailed clinical–epidemiological
escription of the cohort is described elsewhere (Pessanha et al.,
010).
Written informed consent to participate in the study was
btained from each person (or their guardian). All data
ere handled conﬁdentially and anonymously. This study was
eviewed and approved by the Comitê de Ética em Pesquisa
f Secretaria Municipal de Saúde of Belo Horizonte (protocol
37.2005).cal Methods 187 (2013) 114– 120 115
2.2. Recombinant protein expression
For the cloning and expression of the DENV 1, 2, 3 and 4 recom-
binant E proteins, all four DENV serotypes were propagated in
Aedes albopictus C6/36 cells and used as a source of viral RNA for
reverse transcription PCR. DENV-1 was  isolated from a dengue
fever (DF) patient infected during an outbreak in 2002 in Rio
de Janeiro (kindly provided by Ricardo Galler, Instituto Oswaldo
Cruz, Brazil). DENV-2 and DENV-3 were isolated by our labora-
tory from a DF patient and a dengue hemorrhagic fever (DHF)
patient, respectively. The DENV-4 used was the isolate H402276
(Osanai et al., 1983). Viral RNA extraction was performed using the
QIAmp Viral RNA kit (Qiagen, Inc., Valencia, CA, USA). The cDNA
fragments were ampliﬁed by PCR using speciﬁc primers for each
DENV serotype: Den1E-F (ATAGGATCCCGGTGCGTGGGAATAG)
and D1E-R (TATAGTCGACTTA AGTTGCTTCAAACATTTTTCCTATG),
Den2E-F (TATAGGATCCCGTTGCATAGGAATATCAAATAGAG) and
Den2E-R (TATAGTCGACTTATGTTGTCTCAATCATTTGGCC), Den3E-F
(TATAGGATCCAGATGTGTGGGAGTAGGAAAC) and Den3E-R (TAT-
ACTGCAGTTATCTGGCAGTGGCCTCG), and Den4E-F (TATAGGATC-
CCGATGCGTAGGAGTAGGAAAC) and Den4E-R (AGCAAGCTTTTAT-
GTGGACTCAAACATCTTGCC). The PCR products were cloned into a
pGEM-T vector (Promega Corp., Madison, WI,  USA) and subcloned
into a pQE-9 vector (Qiagen, Inc., Valencia, CA, USA). To conﬁrm
the integrity of the ORFs, all four constructions were sequenced at
least 3 times in both orientations (MegaBACE 1000 Sequencer, GE
Healthcare, Buckinghamshire, UK) using pQE universal primers.
The recombinant proteins represent 80% of the N-terminus of
the viral E proteins (E80) of DENV 1, 2, 3 and 4. We chose the N-
terminal 80%-length recombinant E protein (encoding amino acids
1-404) of DENV 1–4 as antigens because together they may be rec-
ognized by speciﬁc antibodies to each DENV serotype. The plasmid
was  transformed into an Escherichia coli host strain M15  contain-
ing the pREP4 plasmid, which encodes the lac repressor and the
kanamycin marker. The resulting recombinant proteins were ana-
lyzed by expression screening, wherein the IPTG-induced bacteria
were lysed directly in a sample buffer and analyzed by SDS-PAGE
(data not shown).
The four recombinant proteins were puriﬁed by nickel afﬁnity
chromatography under denaturing conditions. Based on SDS-PAGE,
the proteins were more than 90% pure and had a molecular mass
of approximately 50 kDa (data not shown). We obtained yields of
up to 10.3, 4.8, 3.3, and 9.0 mg  of Den1E, Den2E, Den3E and Den4E,
respectively, per liter of bacterial culture.
2.3. Enzyme-linked immunosorbent assay
For the IgG-ELISA, Nunc MaxisorpTM 96-well ELISA plates were
ﬁlled with 100 l/well of an equal mixture of the DENV 1–4 recom-
binant proteins (40 ng of each antigen/well) diluted in 0.01 M
carbonate buffer at pH 9.6. After overnight incubation at 4 ◦C, the
plates were washed three times with 300 l/well of phosphate
buffer solution containing 0.05% Tween 20 (PBS-T) and blocked
with 1% bovine serum albumin (BSA) (Sigma–Aldrich, USA) in PBS-
T for 2 h at room temperature (RT). After the washing procedures,
the serum sample was  diluted at 1:50 in PBS-T with 0.1% BSA,
100 l/well of serum dilution was added in duplicate, and the plates
were incubated at RT for 60 min. After washing again, the reac-
tions were developed using 100 l/well of a rabbit-anti-human IgG
antibody conjugated to horseradish peroxidase (Sigma–Aldrich,
USA), diluted at 1:5000 in PBS-T with 0.1% BSA. After incubation
at RT for 60 min, the plates were washed four times, and the sub-
strate o-phenylenediamine dihydrochloride (Sigma–Aldrich, USA)
and 0.03% hydrogen peroxide were added. After incubation at RT
for 10 min, the reaction was  terminated by the addition of 40 l of
2 M sulfuric acid to each well and read at 492 nm using a Biochrom
1 rological Methods 187 (2013) 114– 120
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Fig. 1. The ROC curve for 704 serum samples tested by PRNT and IgG-ELISA. The
AUC, which indicates accuracy, was determined for the mean of the OD duplicates
not shown).16 E.S.d.O. Rocha et al. / Journal of Vi
sys Expert Plus microplate reader. Positive control (serum shown
y PRNT to have DENV 1–4 neutralizing antibody titers ≥ 1:30) and
egative control (PRNT < 1:30) were included in each run.
.4. Plaque reduction neutralization test
The serum samples were screened for speciﬁc antibodies against
ENV-1, 2 and 3 in LLC-MK2 cells using a 50% plaque reduction
riteria as described previously (Russell et al., 1967). The serum was
nactivated (56 ◦C for 30 min) and diluted to a 1:30 screening dilu-
ion in duplicate. The PRNT results were registered in qualitative
positive and negative) terms. Neutralizing antibody titers ≥1:30
ere interpreted as positive and lower titers were interpreted as
egative. Positive and negative controls sera were 2-fold diluted
eginning with a 1:30 dilution until 1:240 to determine the titer of
eutralizing antibodies against DENV 1–3. Each serum was tested
n duplicate, and the plaque-forming unit (PFU) was recorded as
he average of the number observed in each of the two cultures.
he samples (Pessanha et al., 2010) which show discordant results
ith the IgG-ELISA were retested.
.5. Data analysis
Statistics were performed using GraphPad Instat Software, ver-
ion 5.0, and the receiver-operator characteristic (ROC) curve
nalysis was carried out using MedCalc Software, version 7.3.0.0.
his curve optimizes the interpretation of the ELISA results when
here are well-deﬁned positive and negative populations available
or analysis. The ROC curve is a graphical plot of the sensitivity
ersus “100 − speciﬁcity” for a binary classiﬁer system, using var-
ous cutoff values. This allows the cutoff value that gives the best
alance of sensitivity and speciﬁcity to be selected for the test being
onsidered (Zweig and Campbell, 1993). To determine which cutoff
alue provided the most accurate result, the area under the curve
AUC) was calculated.
. Results
.1. Performance of IgG ELISA
To evaluate the IgG-ELISA, 704 serum samples, tested previously
y PRNT, were used to investigate the presence of speciﬁc antibod-
es against DENV. A total of 100 PRNT-positive samples and 604
RNT-negative samples were used. The results associated with the
ean optical density obtained with an IgG-ELISA of each of the 704
erum samples were analyzed to establish the cutoff value by the
OC curve method (Fig. 1). The results were considered positive
hen the optical density at 492 nm was higher than 0.524.
The results summarized in Table 1 indicate that 97% of the
amples tested by IgG-ELISA and PRNT were concordant between
oth assays. Positive samples with both assays were assigned as
rue positives (TP), and those samples whose results were negative
or both assays were assigned as true negatives (TN). Using PRNT
esults as true values, the false-negative rate of the IgG-ELISA test
as 9% (9/100), and the false-positive rate was 1.9% (12/604).
able 1
omparison between PRNT and IgG-ELISA tests (positive and negative results).
ELISA/PRNT results No. of samples % of total
ELISA+/PRNT+ (TP) 91 12.9
ELISA−/PRNT− (TN) 592 84.1
ELISA+/PRNT− (FP) 12 1.7
ELISA−/PRNT+ (FN) 9 1.3
Total 704 100
P, true positive; TN, true negative; FP, false positive; FN, false-negative.and was  equal to 0.950, resulting in 91% sensitivity and 98% speciﬁcity, for a cutoff
value of 0.524.
The AUC indicated that the IgG-ELISA was, on average, 95% accu-
rate, and the 95% conﬁdence interval of the AUC for IgG-ELISA
ranged from 93.2 to 96.5% (Table 2). The optimal cutoff point of
0.524 resulted in a sensitivity of 91% and a speciﬁcity of 98% as
shown in Table 2 and Fig. 1. This optimal cutoff point helped to
classify tentatively the samples as TP, TN, false positive (FP) or false
negative (FN). Of the 100 PRNT-positive serum samples, 91 were
considered to be TP because the samples presented IgG-ELISA read-
ings above the optimized cutoff point, while 9 PRNT-positive sera
were diagnosed as FN because the IgG-ELISA results were below
this cutoff point. Among the 604 PRNT-negative sera, 592 serum
samples presented values below the ROC-optimized cutoff when
tested by IgG-ELISA and were hence considered to be TN (Fig. 2). The
optimal IgG-ELISA cutoff was associated with a positive likelihood
ratio (LR) of 45.80 and a negative LR of 0.09 (Table 2). The proba-
bility of TP serum samples with positive ELISA test results (positive
predictive value) was  88.3%, while the probability of TN serum sam-
ples with negative IgG-ELISA test results (negative predictive value)
was  98.5% (Table 2).
Additionally, all 9 FN samples were negative in the Panbio
Dengue IgM capture ELISA, except one. In contrast, all 12 FP sam-
ples were positive by the PanBio Dengue IgG Capture ELISA (dataTable 2
ROC analysis of the IgG-ELISA performance in identiﬁcation of prior DENV infections
(n  = 704 serum samples).
Indice IgG-ELISA
AUC 0.950
AUC at 95% conﬁdence interval 0.932–0.965
Sensitivity (%) 91.0
Speciﬁcity (%) 98.0
Test positive predictive value (%) 88.3
Test negative predictive value (%) 98.5
Optimal test cutoff 0.524
Positive likelihood ratio 45.80
Negative likelihood ratio 0.09
Prevalence 14.2%
AUC, area under the curve.
E.S.d.O. Rocha et al. / Journal of Virological Methods 187 (2013) 114– 120 117
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determination in individual serum specimens of the 704 samples
by the use of PRNT and IgG-ELISA in a two-dimensional distribu-
tion. The correlation between the anti-dengue IgG-ELISA and PRNT
values results in  = 0.537 after Spearman’s correlation (P < 0.0001,
95% conﬁdence interval for  between 0.48 and 0.59).
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ndicates the cutoff value (0.524).
The samples that were negative by IgG-ELISA and positive by
RNT presented neutralizing antibody titers ranging from 1:60 to
1:120 (representative data are shown in Fig. 3). As shown in Fig. 3,
he IgG-ELISA was able to detect low titers (1:30) as well as high
iters of neutralizing antibodies (>1:120).
The graph in Fig. 4 presents the results of speciﬁc neutralizing
ntibody determination in 100 individual serum specimens by the
se of PRNT and IgG-ELISA in a two-dimensional distribution. An
nalysis using a Kruskal–Wallis test revealed that the apparent dif-
erence between the three medians are not signiﬁcant statistically
P = 0.1899).
Regarding the speciﬁc serotype, the IgG-ELISA is able to detect,
ith similar sensitivity, neutralizing antibodies to DENV-1, 2 and 3,
s the sensitivity for each serotype was 90.3, 93.1 and 88.9%, respec-
ively. These data were determined by calculating the number of TP
esults divided by the sum of the TP results plus the number of FP
esults.
Neutralizing antibodies to DENV-4 were investigated addition-
lly in all nine FN sera samples, but none had detectable titers by
RNT (data not shown).
. Discussion
Although PRNT has been used for over 30 years as a quantita-
ive method to detect anti-DENV neutralizing antibodies, the assay
s laborious to perform, and a period of at least 7 days is required
o obtain accurate diagnostic results; however, it is still considered
he gold standard for determining immunity against DENV. Sev-
ral dengue immunoenzymatic assays have been developed with
ifferent formats as alternatives to PRNT because they are simple,
apid, and easy to perform (de Paula and Fonseca, 2004). Further-
ore, the whole virus production required for neutralizing tests has
otential biohazards associated with the handling of live virus dur-
ng the preparation of diagnostic reagents. Thus, the replacement
f neutralizing tests is an attractive possibility.
In recent years, numerous ELISA kits have been developed and
sed to diagnose dengue infections (Buerano et al., 2000; dos Santos
t al., 2007; Nunes et al., 2011; Palmer et al., 1999; Parida et al.,cal Methods 187 (2013) 114– 120
2001; Sathish et al., 2002; Vaughn et al., 1999), but there have been
studies examining the detection of anti-DENV antibodies using the
four serotype E recombinant proteins (Cuzzubbo et al., 2001; dos
Santos et al., 2007; Ludolfs et al., 2002; Videa et al., 2005).
Here, we have exploited a bacterial expression system for the
production of E proteins. The E gene was  truncated at its carboxy
terminus to remove the hydrophobic membrane anchor segment
to maximize the expression of the protein, as recommended by
others in different systems (Delenda et al., 1994; Men  et al., 2000,
1991; Raviprakash et al., 2000). Bacterial expression is perhaps the
most employed commonly expression system for the production of
non-glycosylated recombinant proteins. The organism is relatively
simple to manipulate, and expressed proteins are puriﬁed easily
under denaturing conditions. Additionally, refolding of the protein
is not necessary for diagnostic purposes (Tripathi et al., 2008).
Anti-DENV IgG antibodies in human sera cross-react with all
four dengue virus serotypes (Nawa et al., 2000) and even with
other ﬂaviviruses (Cuzzubbo et al., 1999; Rivetz et al., 2009; Vaughn
et al., 1999; Wu et al., 1997). Hence, we proposed the use of a mix-
ture of the four serotype recombinant DENV antigens as reagents.
Although an indirect IgM-ELISA with a mixture of recombinant
antigens bound to a polystyrene plate has already been evaluated
(Videa et al., 2005), this IgG-ELISA is the ﬁrst immunoenzymatic
assay based on recombinant DENV E proteins to have comparable
results to PRNT. Moreover, IgG antibodies against DENV 1–3 are
detected simultaneously by our test using a single serum dilution
rather than additional dilutions for each serotype neutralization, as
required by PRNT.
The comparative evaluation performed on the MedCalc pro-
gram resulted in a cutoff that represents the distinction limit
between positive and negative samples. An ELISA result equal to
or lower than the cutoff is negative, and a higher result is posi-
tive. Although 683 (97%) samples evaluated by PRNT and IgG-ELISA
showed concordant results, 21 samples (3%) tested by IgG-ELISA
were discordant to the PRNT results. Two hypothesis may explain
the differences in the results: (i) Positive samples veriﬁed only by
PRNT have undetectable IgG levels by IgG-ELISA, whereas speciﬁc
IgM is the ﬁrst class of neutralizing antibodies that result from a
recent DENV infection; or (ii) the recombinant antigens used in
this study have epitopes that are recognized by speciﬁc antibodies
(a phenomenon known as cross-reaction) of other viruses of the Fla-
vivirus genus, such as Yellow fever virus (YF). However, the second
hypothesis is unlikely because 83% of the individuals tested by our
assay were vaccinated previously against YF (Pessanha et al., 2010).
This number represents more than ﬁve times the positive IgG anti-
dengue samples. Moreover, no West Nile virus, Japanese encephalitis
virus (JE) or Saint Louis encephalitis virus infections were reported
in Brazil until the end of the sampling collection. In addition, there
were no cases of DENV-4 reported in the sample collection period.
The sensitivity and the speciﬁcity results obtained for the
IgG-ELISA are comparable to other serological methods that are
available commercially for the detection of antibodies to DENV
in Brazil, such as Panbio ELISA Dengue IgG, Panbio Dengue Duo
Cassette and Pathozyme Dengue IgG (ANVISA, 2003). Two commer-
cial ELISAs, the PanBio Dengue IgM capture ELISA and the PanBio
Dengue IgG capture ELISA (PanBio Pty Ltd., Brisbane, Australia), also
detect cross-reactive antibodies against JE and YF virus (Rivetz et al.,
2009; Yew et al., 2009).
The results reported herein indicate that our ELISA, based on
pooled recombinant E antigens, provided a reliable diagnosis of
DENV infections comparable to PRNT because high sensitivity and
speciﬁcity were obtained by the IgG-ELISA and were associated
with high accuracy. In addition, IgG-ELISA OD values also presented
a good correlation to neutralizing antibody titers as detected by
PRNT (Fig. 3), allowing inferences about the antibody levels in a
similar manner to PRNT. Furthermore, recombinant antigen-based
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ssays, compared to virus-infected cell culture antigen assays,
an provide a valuable resource for serodiagnosis because they
re potentially cheaper, and the cost of most commercial kits
or dengue diagnosis is a limitation in many dengue-endemic
ountries.
Epidemiological studies may  play major role in evaluating the
revalence of dengue fever and in providing indicative values that
eﬂect the effectiveness of vector control strategies, especially in
ndemic areas where DENV infections are frequent (Teixeira et al.,
005). According to the present study conducted in 2006 and
007, a considerable proportion of the population in Belo Hori-
onte had anti-DENV IgG antibodies (14.2%), which increases the
isk of DHF/DSS cases once dengue becomes endemic in this city.
ccording to the Secretaria de Vigilância em Saúde (SVS), DENV-3
as introduced recently into Minas Gerais State. This introduction
orrelates well with our ﬁndings of serotype-speciﬁc dengue cases,
s types 1 and 2 represented 91% of dengue infections determined
y PRNT in our study.
Several serological survey studies have been conducted in Brazil
n the last few decades involving randomly collected samples tested
y PRNT, hemagglutination inhibition, or immunoenzymatic assays
Figueiredo et al., 2004; Lima et al., 2007, 1999; Siqueira et al., 2004;
asconcelos et al., 2000, 1999). However, this work is the ﬁrst sero-
ogical survey effort to compare PRNT to an IgG-ELISA based on
ENV recombinant antigens.
DENV possesses epitopes that are shared by other ﬂaviviruses,
uch as JEV, and as a result, antibodies generated against cross-
eactive epitopes during infection may  give rise to false-positive
ests (Koraka et al., 2002; Vaughn et al., 1999). This cross-reactivity
ccurs more often with IgG antibodies and less often with IgM anti-
odies (Cuzzubbo et al., 1999). The IgG-ELISA described in this study
as proven to be very reliable and presented no cross-reaction to
nti-YF virus antibodies.
. Conclusions
In summary, our IgG-ELISA has proven to be rapid and easy to
erform, overcomes some of the limitations associated with PRNT,
nd has great potential for use in the serodiagnosis and seroepi-
emiological study of DENV infections. In addition, the assay has
he potential for use in other applications, such as vaccine studies
n clinical trials, as the system is able to detect effectively dengue
eutralizing antibodies. Additionally, the high speciﬁcity of IgG-
LISA in detecting DENV antibodies enables its use in areas where
xposure to Flavivirus antigens of YFV occurs through vaccination.
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